MAP3K5

MAP3K5 Full Name

mitogen-activated protein kinase kinase kinase 5

MAP3K5 Introduction

MAP3K5, also known as apoptosis signal-regulating kinase 1 (ASK1), has emerged as a highly important stress-response kinase in modern biomedical research because of its central role in inflammation, oxidative stress, and programmed cell death. For researchers and drug developers working on cancer, neurodegenerative disorders, cardiovascular injury, or inflammatory diseases, understanding MAP3K5 is increasingly critical due to its position upstream of the JNK and p38 MAPK signaling pathways. Under normal physiological conditions, ASK1 activity is tightly controlled by regulatory proteins such as thioredoxin (Trx), but excessive reactive oxygen species (ROS), endoplasmic reticulum stress, cytokines, bacterial toxins, or viral infections can rapidly activate the kinase. Once activated, MAP3K5 triggers cellular stress signaling cascades that influence apoptosis, immune responses, mitochondrial dysfunction, and tissue remodeling. Because oxidative stress and chronic inflammation are common pathological drivers across multiple diseases, MAP3K5 has become a major focus for translational medicine and targeted therapeutic development.

One of the most clinically relevant aspects of MAP3K5 is its complex and context-dependent role in cancer biology. Multiple studies have demonstrated that ASK1 can function as a tumor suppressor by promoting ROS-mediated apoptosis and eliminating damaged cells before malignant transformation occurs. This mechanism is particularly important in cancers associated with genomic instability and oxidative stress. However, more recent evidence also suggests that persistent or dysregulated ASK1 signaling may contribute to tumor progression, inflammatory tumor microenvironments, metastasis, and resistance to therapy in certain cellular contexts. This dual role has created strong interest in precision targeting strategies that either inhibit or restore MAP3K5 activity depending on tumor type and disease stage. Researchers are also investigating how upstream regulators including TRAF proteins, ubiquitination pathways, and redox-sensitive proteins modulate ASK1 activation. As precision oncology increasingly moves toward pathway-specific intervention, MAP3K5 is being explored not only as a prognostic biomarker but also as a therapeutic target for combination therapies involving kinase inhibitors, ROS modulation, and immune-based treatments.

Beyond oncology, MAP3K5 has significant implications in neurodegenerative diseases, cardiovascular disorders, metabolic dysfunction, inflammatory injury, and drug-induced toxicity. Excessive ASK1 activation has been linked to neuronal apoptosis in disorders characterized by chronic oxidative stress, including Parkinson's disease and Alzheimer's disease models. In cardiovascular tissues, ASK1 contributes to ischemia-reperfusion injury, cardiac remodeling, endothelial dysfunction, and inflammatory signaling. Recent pharmaceutical research has accelerated the development of highly selective ASK1 inhibitors, including benzoheterocyclic amide derivatives with nanomolar inhibitory activity and favorable pharmacokinetic profiles. Importantly, ASK1 inhibition has also shown therapeutic promise in protecting against aminoglycoside-induced hearing loss, where ROS-driven activation of JNK and p38 pathways causes irreversible cochlear hair cell death. Experimental studies demonstrated that genetic deletion or pharmacological inhibition of ASK1 significantly reduced hair cell apoptosis without compromising antibiotic efficacy against bacterial pathogens. These findings highlight MAP3K5 as a versatile molecular target with broad translational potential across oncology, neurology, otology, inflammation research, and precision drug development.

Alternate Names for MAP3K5

MAP3K5; mitogen-activated protein kinase kinase kinase 5; ASK1; MEKK5; MAPKKK5; ASK-1; MEKK 5; MEK kinase 5; MAP/ERK kinase kinase 5; MAPK/ERK kinase kinase 5; apoptosis signal regulating kinase 1; apoptosis signal-regulating kinase 1

• 1.Nguyen K, et al.; MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types. Front Biosci (Landmark Ed). 2022, 27(5):167.
  2.Khan Y, et al.; ASK1 Signaling in Cancer: Pathogenic Driver or Therapeutic Target? J Biochem Mol Toxicol. 2025, 39(11):e70605.